Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...

The Delhi HC ruling does not abolish patents or endorse blanket early entry. Instead, it stresses courts may intervene ...

The availability of a more affordable biosimilar is expected to improve access to advanced cancer treatment not just in major ...

Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

ImmunityBio, Inc. , a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) clinical program in non-small cell lung cancer (NSCLC) ...

The court directed Zydus to maintain detailed and audited records of its sales during this period so that the innovator can ...

CHENNAI: A division bench of the Delhi High Court on Monday allowed Indian drugmaker Zydus Lifesciences to sell and market ...

Nivolumab is a monoclonal antibody-based immunotherapy used in the treatment of several cancers, including lung and head-and-neck cancers| Business News ...

Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...

Exelixis, Inc. EXEL reported preliminary, unaudited financial results for fiscal year 2025, issued financial guidance for ...